179 related articles for article (PubMed ID: 12006509)
1. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
[TBL] [Abstract][Full Text] [Related]
2. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
4. Clonal heterogeneity of p53 mutations in ovarian cancer.
Manahan KJ; Taylor DD; Gerçel-Taylor C
Int J Oncol; 2001 Aug; 19(2):387-94. PubMed ID: 11445857
[TBL] [Abstract][Full Text] [Related]
5. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
7. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
8. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
9. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.
Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M
N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
11. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
12. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
13. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
16. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
Abe A; Ikawa H; Muguruma H; Maeda Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
18. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
19. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
[TBL] [Abstract][Full Text] [Related]
20. Absence of hereditary p53 mutations in 10 familial leukemia pedigrees.
Felix CA; D'Amico D; Mitsudomi T; Nau MM; Li FP; Fraumeni JF; Cole DE; McCalla J; Reaman GH; Whang-Peng J
J Clin Invest; 1992 Aug; 90(2):653-8. PubMed ID: 1644930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
